Event rates, hospital utilization, and costs associated with major complications of diabetes: A multicountry comparative analysis

PLoS Medicine

Volumn 7, Issue 2, 2010, Pages

  Clarke, Philip M ^a   Glasziou, Paul ^b   Patel, Anushka ^c   Chalmers, John ^c   Woodward, Mark ^c   Harrap, Stephen B ^d   Salomon, Joshua A ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLUCOSE; INDAPAMIDE PLUS PERINDOPRIL;

AGED; ARTICLE; ASIA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; EASTERN EUROPE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL BED; HOSPITAL PURCHASING; HUMAN; HYPERTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; STROKE; UNITED STATES; WORLD HEALTH ORGANIZATION; COMPARATIVE STUDY; COST OF ILLNESS; ECONOMICS; HOSPITALIZATION; MIDDLE AGED; MORTALITY; STATISTICS;

AGED; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED;

EID: 77649085616     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000236     Document Type: Article

References (31)

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
2. Gu K, Cowie CC, Harris MI (1998) Mortality in adults with and without diabetes in a national cohort of the U. S. population, 1971-1993. Diabetes Care 21: 1138-1145.
3. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM (2001) Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 322: 1389-1393.
4. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290: 1884-1890.
5. Selby JV, Ray GT, Zhang D, Colby CJ (1997) Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 20: 1396-1402.
6. Ramachandran A, Ramachandran S, Snehalatha C, Augustine C,Murugesan N, et al. (2007) Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care 30: 252-256.
7. Rubin R, Altman WM, Mendelson DN (1994) Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 78: 809A-809F.
8. Narayan KM, Zhang P, Kanaya AM, Williams DE, Engelgau MM, et al. (2006) Diabetes: The pandemic and potential solutions. Disease control priorities in developing countries. 2nd edition. New York: Oxford University Press. pp 591-604.
9. International Diabetes Federation (2006) Diabetes atlas. 3rd Edition. Brussels: International Diabetes Federation.
10. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, W, et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572.
11. Adam T, Evans DB, Murray CJL (2003) Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 1: 3.
12. ADVANCE Management Committee (2001) Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 44: 1118-1120.
13. Wooldridge JM (2001) Econometric analysis of cross section and panel data. Boston: MIT Press.
14. Diggle PJ, Heagerty PJ, Liang K-Y, Zeger SL (2002) Analysis of longitudinal data. 2nd Edition. Oxford: Oxford University Press.
15. Rabe-Hesketh S, Skrondal A (2005) Multilevel and longitudinal modeling using stata. College Station (Pennsylvania): Stata Press.
16. Liang KY Zeger SL (1986) Longitudinal data analysis using generalized linear models Biometrika 73: 13-22.
17. Jones AM (2000) Health econometrics. Culyer AJ, Newhouse JP, eds. Handbook of health economics. Edition 1, volume 1, chapter 6. Amsterdam: Elsevier. pp 265-344.
18. World Health Organization (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization.
19. World Health Organization (2009) World health statistics 2009. Geneva: World Health Organization.
20. Rubin RJ, Altman WM, Mendelson DN (1994) Health expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 78: 809A-809F.
21. Henriksson F, Agardh C-D, Berne C, Bolinder J, Lönnqvist F, et al. (2000) Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 248: 387-396.
22. Jönsson B (2002) Revealing the cost of Type II diabetes in Europe. Diabetologia 45: S5-S12.
23. Hogan P, Dall T, Nikolov P, American Diabetes Association (2003) Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26: 917-932.
24. American Diabetes Association (2008) Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31: 596-615.
25. Rayappa PH, Raju KNM, Kapur A, Bjork S, Sylvest C, Kumar DMD (1999) The impact of socio-economic factors on diabetes care. Int J Diab Dev Countries 19: 7-19.
26. Wang W, Fu CW, Pan CY, Chen W, Zhan S, et al. (2009) How do type 2 diabetes mellitus-related chronic complications impact direct medical cost in four major cities of urban China? Value Health 12: 923-929.
27. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR (2005) Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 48: 868-877.
28. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, et al. (2005) Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142: 323-332.
29. Xie X, Vondeling H (2008) Metformin cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health 11: S23-S32.
30. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Zhang P (2007) Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 30: 2548-2552.
31. Clarke P, Gray A, Legood R, Briggs A, Holman R (2003) The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 20: 442-450.